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ABSTRACT 
 
Objectives 
To compare 1) Short Form-36 (SF-36) Physical (PCS) and Mental (MCS) Component 
Summaries, scale scores and Short Form-6 dimensions (SF-6D) between rheumatoid (RA) and 
psoriatic arthritis (PsA) patients and Norwegian general population controls and 2) 
improvements in these measures between RA and PsA patients. 
 
Methods 
ANCOVA analyses were performed to compare SF-36 measures between first-time enrolled 
RA (n=3898) and PsA (n=1515) patients from the prospective observational multicenter NOR-
DMARD study (6 months follow-up) and general population controls (n=2323).  
 
Results 
In age and gender-adjusted analyses PsA compared to  RA patients had similar PCS, MCS and 
SF-6D (p≥0.14), worse vitality and general health, but better physical functioning at 0/6 
months (p≤0.03).  With additional DAS28-adjustment as a proxy for joint inflammation, PCS, 
most scale scores and SF-6D were worse in PsA than RA patients at 0/3/6 months (p≤0.01). 
PCS was more impaired than MCS both in RA and PsA compared with general population 
controls (p≤0.001). Mean 3- and 6-month improvements after DMARD treatment were 
larger in RA than PsA patients for bodily pain, vitality and mental health (p≤0.02). 
 
Conclusions   
HRQoL was overall similar in RA and PsA patients- with a tendency to worse scores in PsA- 
and worse compared with Norwegian general population controls. 
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INTRODUCTION 
Health-Related Quality of Life (HRQoL) is part of the core set of data to be collected in 
patients with psoriatic arthritis (PsA) and recognized to be of major importance also in other 
rheumatic diseases, including rheumatoid arthritis (RA).1, 2 HRQoL has been found to be 
impaired in patients with inflammatory arthritides compared with the general population.3-6 
In smaller observational studies performed 1-2 decades ago similar HRQoL in RA and PsA 
patients were described,7, 8 but also differences in Short Form-36 (SF-36) scale scores.5  
To our knowledge no large, prospective observational study has compared HRQoL between 
RA and PsA patients and the general population using the widely recognized SF-36. 
The aim of this study was to compare SF-36 Physical and Mental Component Summaries 
(PCS, MCS), scale scores as well as short form-6 dimensions utility score (SF-6D) between RA 
and PsA patients from a large prospective observational study, as well as with general 
population controls. Furthermore, we aimed to compare improvements in PCS, MCS and 
scale scores between RA and PsA patients from baseline to 3 and 6 months follow-up after 
initiation of treatment with disease-modifying anti-rheumatic drugs (DMARDs). 
 
METHODS  
Patients 
We included first-time enrolled RA and PsA patients from the prospective longitudinal 
observational multicentre NORwegian-Disease Modifying Anti-Rheumatic Drug (NOR-
DMARD) study,9, 10 starting synthetic and/or biologic DMARDs between 1 December 2000 
and 6 November 2012 and followed until 1 May 2013 or until stopping DMARD medication. 
The RA and PsA diagnoses were given by the treating rheumatologist after clinical 
judgement. Analyses included baseline, 3- and 6-month follow-up. Written informed consent 
was obtained from each patient. The study was approved by the National Data Inspectorate 
and by the Regional Committee for Medical and Health Research Ethics in Eastern Norway. 
For comparison, we included SF-36 Norwegian normative data from 2323 individuals 
collected in 1996.11 
 
Short Form-36 and short form-6 dimensions 
The Norwegian translation of SF-36 version 1, used in this study, is validated in Norwegian 
RA patients.12 PCS and MCS were calculated as described by Ware et al.13 Norm-based scale 
scores were computed by subtracting the general population’s respective mean scale score 
from the 0-100 scale scores, divided by the standard deviation of the data from the general 
population. Each of these values were multiplied by 10 and 50 was added, as described by 
Ware et al.14 SF-6D was calculated from SF-36 according to the algorithm developed by 
Brazier et al.15 
 
Statistics 
Demographic and baseline characteristics are shown as medians (25th, 75th percentiles) for 
non-normally and means (SD) for normally distributed data. Continuous variables were 
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compared using independent t-test, Mann-Whitney U-test or ANOVA, as appropriate. 
Prespecified age and gender-adjusted ANCOVA analyses were performed to compare PCS, 
MCS, scale scores and SF-6D between RA, PsA patients and general population controls at 
baseline, and between RA and PsA patients with and without additional adjustment for the 
respective 28-joint disease activity scores (DAS28) at baseline and after 3- and 6-month 
follow-up. Prespecified ANCOVA analyses were performed to compare changes in PCS, MCS, 
scale scores and SF-6D from baseline to 3 and 6 months follow-up, adjusted for age, gender 
and the respective baseline values. Radar diagrams were made to visualize differences in 
scale scores (0 worst, 100 best) between RA/PsA patients and the Norwegian general 
population. Statistical tests were performed using SPSS V.23.0 for Windows. The analyses 
were performed as completer analyses and without adjustment for multiple comparisons. 
 
RESULTS 
RA patients (n=3898), PsA patients (n=1515) and general population controls (n=2323) had 
mean (SD) age 55.9 (31.6)/ 48.1 (12.6)/ 44.9 (16.5) years and 71.4/ 50.3/ 51.3% were 
females, respectively. Baseline mean (SD) DAS28 was worse in RA (4.9 (1.4)) than PsA (4.2 
(1.3)) patients (online supplementary Table S1). 
 
Analyses adjusted for age and gender 
SF-36 PCS, MCS, scale scores and SF-6D were worse in RA and PsA patients compared with 
the general population (Table 1), but improved during follow-up (online supplementary 
Table S2).  
 
 
Table 1 Unadjusted analyses and analyses adjusted for age and gender of baseline SF-36 component 
summaries, norm-based scale scores and SF-6D utility scores 
Baseline 
Component 
summary/ scale score 
Unadjusted analyses, mean (SD) 
p-value 
Adjusted analyses,                  
estimated marginal means (95%CI)  
p-value  
General 
population 
RA PsA 
General 
population 
RA PsA 
PCS 
50.0 (10.1) 
(n=2012) 
29.7 (9.9) 
(n=3898) 
30.5 (9.5) 
(n=1515) 
<0.0011,2 
0.023  
49.7     
(49.2-50.1) 
30.5    
(30.2-30.8)  
30.4    
(29.9-30.9)  
<0.0011,2 
0.693  
MCS 
50.0 (10.2) 
(n=2012) 
46.8 (11.3) 
(n=3898)  
47.1 (11.4) 
(n=1515)  
<0.0011,2 
0.593  
  50.0    
(49.5-50.5) 
47.1    
(46.8-47.5)  
47.1    
(46.5-47.6)  
<0.0011,2 
0.903  
SF-6D 
0.80 (0.14) 
(n=2071) 
0.60 (0.12) 
(n=3787) 
0.61 (0.12) 
(n=1491) 
<0.0011,2 
0.173 
0.80     
(0.80-0.81) 
0.61    
(0.60-0.61) 
0.60    
(0.60-0.61) 
<0.0011,2 
0.453 
Physical Functioning 
49.4 (10.8) 
(n=2235) 
27.7 (14.5) 
(n=3898) 
30.5 (13.5) 
(n=1515) 
<0.0011,2,3  
48.9     
(48.3-49.4) 
29.0     
(28.5-29.4) 
30.2    
(29.6-30.9) 
<0.0011,2 
0.0013    
Role Physical 
49.6 (10.3) 
(n=2207) 
32.9 (9.1) 
(n=3898) 
34.0 (9.9) 
(n=1515) 
<0.0011,2 
0.0013  
49.4     
(49.0-49.8) 
33.5    
(33.2-33.8) 
33.9     
(33.4-34.4) 
<0.0011,2 
0.163    
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Bodily Pain 
49.6 (10.3) 
(n=2287) 
33.5 (7.5) 
(n=3898) 
33.6 (7.2) 
(n=1515) 
<0.0011,2 
0.963  
49.4     
(49.1-49.8) 
34.0     
(33.7-34.2) 
33.5    
(33.1-33.9) 
 <0.0011,2 
0.073    
General Health  
49.6 (10.3) 
(n=2183) 
37.5 (9.5) 
(n=3898) 
36.8 (9.7) 
(n=1515) 
<0.0011,2 
0.023  
49.5     
(49.0-49.9) 
37.9    
(37.6-38.3) 
36.7    
(36.2-37.2) 
<0.0011,2,3 
Vitality  
49.8 (10.3) 
(n=2270) 
39.6 (10.1) 
(n=3898) 
39.3 (10.3) 
(n=1515) 
<0.0011,2 
0.693  
49.9     
(49.5-50.3) 
40.4    
(40.1-40.8) 
39.4    
(38.9-39.9) 
<0.0011,2,3 
Social Functioning  
49.5 (10.5) 
(n=2311) 
39.1 (12.6) 
(n=3898) 
39.5 (12.3) 
(n=1515) 
<0.0011,2 
0.593  
49.4     
(48.9-49.9) 
39.8     
(39.4-40.2) 
39.5     
(38.9-40.1) 
<0.0011,2 
0.403  
Role Emotional  
49.8 (10.2) 
(n=2182) 
40.2 (13.6) 
(n=3898) 
41.6 (13.6) 
(n=1515) 
<0.0011,2 
0.0023  
49.5     
(49.0-50.0) 
40.6     
(40.2-41.1) 
41.5    
(40.8-42.1) 
<0.0011,2 
0.033  
Mental Health  
49.8 (10.3) 
(n=2255) 
44.3 (11.5) 
(n=3898) 
44.7 (11.1) 
(n=1515) 
<0.0011,2 
0.633  
49.8     
(49.4-50.3) 
44.8    
(44.5-45.2) 
44.7    
(44.2-45.3) 
<0.0011,2 
0.763  
1General population compared to RA patients; 2General population compared to PsA patients; 3RA 
patients compared to PsA patients. CI, confidence interval; MCS, mental component Summary; PCS, 
physical component summary; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF-6D, short form-6 
dimensions utility score 
 
 
PCS and MCS were not statistically different in RA compared to PsA patients, while physical 
functioning was better and general health and vitality worse in PsA patients at all time-
points. Bodily pain was similar between RA and PsA patients at baseline, but slightly worse in 
PsA patients at 3 and 6 months (Table 1, online supplementary Table S2). 
 
Analyses adjusted for age, gender and DAS28 
In analyses adjusted for DAS28 in addition to age and gender, PsA patients had significantly 
worse PCS and SF-6D at all time-points compared to RA patients. Baseline MCS and all scale 
scores, except role emotional, were worse in PsA compared to RA patients. At 3 and 6 
months bodily pain, general health, vitality, social functioning and mental health were worse 
and the remaining scale scores similar in PsA compared to RA patients (online 
supplementary Table S3).  
 
Longitudinal analyses adjusted for age, gender and baseline values of the respective scores 
RA and PsA patients had similar improvements in PCS, MCS, all scale scores and SF-6D at 3 
and 6 months, except for larger improvements in bodily pain, vitality and mental health in 
the RA patients (Table 2, adjusted analyses and supplementary Table S4, unadjusted 
analyses). 
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Table 2 Mean improvements from baseline until 3 and 6 months follow-up, adjusted for age, gender 
and the respective baseline values  
Component summary/ 
 scale score 
Adjusted analyses,                         
mean change (95% CI) from baseline until 3 months* p-value 
RA PsA 
PCS 4.7 (4.3-5.0) n=3081 4.4 (3.9-4.9) n=1183 0.42 
MCS 1.8 (1.4-2.1) n=3081 1.5 (1.0-2.0) n=1183 0.41 
SF-6D 0.04 (0.03-0.04) n=2323 0.03 (0.03-0.04) n=872 0.06 
Physical Functioning 4.6 (4.2-5.0) n=3197 4.6 (4.2-5.2) n=1217 0.93 
Role Physical 4.2 (3.8-4.6) n=3178 4.3 (3.7-4.8) n=1208 0.83 
Bodily Pain 5.8 (5.5-6.1) n=3187 5.1 (4.6-5.5) n=1214 0.004 
General Health 1.4 (1.1-1.7) n=3149 1.3 (0.9-1.7) n=1203 0.61 
Vitality 3.8 (3.5-4.2) n=3173 2.8 (2.3-3.4) n=1209 0.002 
Social Functioning 3.7 (3.3-4.1) n=3201 3.3 (2.8-3.9) n=1216 0.31 
Role Emotional 2.2 (1.8-2.7) n=3161 2.8 (2.1-3.4) n=1197 0.20 
Mental Health 2.5 (2.2-2.8) n=3170 1.9 (1.4-2.4) n=1210 0.008 
Component summary/ scale 
score 
Adjusted analyses,                        
mean change (95% CI) from baseline until 6 months* p-value 
RA PsA 
PCS 5.6 (5.2-6.0) n=2605 5.4 (4.8-5.9) n=1034 0.49 
MCS 2.5 (2.2-2.9) n=2605 2.1 (1.5-2.6) n=1034 0.18 
SF-6D 0.04 (0.04-0.05) n=1832 0.04 (0.03-0.05) n=721 0.42 
Physical Functioning  5.8 (5.4-6.3) n=2676 6.3 (5.6-7.0) n=1052 0.26 
Role Physical  5.6 (5.2-6.1) n=2670 5.6 (5.0-6.2) n=1048 0.91 
Bodily Pain  6.7 (6.3-7.0) n=2675 5.8 (5.3-6.3) n=1051 0.005 
General Health  1.7 (1.4-2.1) n=2659 1.3 (0.9-1.8) n=1050 0.17 
Vitality  4.7 (4.3-5.1) n=2668 3.9 (3.3-4.4) n=1051 0.02 
Social Functioning  4.7 (4.3-5.1) n=2687 4.4 (3.8-5.0) n=1054 0.39 
Role Emotional  3.1 (2.6-3.6) n=2657 3.4 (2.7-4.2) n=1045 0.44 
Mental Health  3.2 (2.9-3.6) n=2665 2.5 (2.0-3.0) n=1052 0.02 
*estimated marginal means; CI, confidence interval; SD, standard deviation; MCS, mental component 
summary; PCS, physical component summary;  PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF-
6D, short form-6 dimensions utility score 
 
 
Graphical comparisons of scale scores 
Estimated marginal means of baseline, 3- and 6-month SF-36 scale scores adjusted for age 
and gender (Figure) as well as DAS28 (figure not shown) were impaired in RA and PsA 
patients compared with the general population, but showed only small differences between 
RA and PsA patients.  
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DISCUSSION 
In this large prospective observational multicentre study SF-36 PCS, MCS as well as the utility 
measure SF-6D were comparable between RA and PsA patients at baseline and at 6 months 
follow-up in age and gender-adjusted analyses. Furthermore, PsA patients had worse 
general health and vitality, but better physical functioning at all time-points, as well as more 
bodily pain at 3 and 6 months. With adjustment for DAS28 in addition to age and gender, 
PsA compared to RA patients had worse PCS, SF-6D, general health, vitality, bodily pain, 
social functioning and mental health at all time-points. 
Further, the study shows that levels of physical HRQoL were more impaired than mental 
HRQoL in patients with RA and PsA compared with Norwegian general population controls.  
Improvements in scale scores from baseline until 3 and 6 months were similar between RA 
and PsA patients during treatment with DMARDs, except for larger improvements in bodily 
pain, vitality and mental health in RA. 
We have chosen to present norm-based scale scores to facilitate interpretation and 
comparison across different countries and populations.14, 16 Still, interpretation of the 
findings is not straight-forward; the statistically significant differences between RA and PsA 
patients may not always be clinically significant. As visualized in radar diagrams (Figure) the 
differences in scale scores between RA and PsA patients are small. Still, for e.g. general 
health the difference between RA and PsA patients at different time-points is of similar 
magnitude as the improvement in general health from baseline until 6 months both for RA 
and PsA patients and hence of probable clinical significance.  
The study underlines the severe impact of both RA and PsA on HRQoL reflected through SF-
36, which is in line with a smaller observational study3 as well as clinical trials.4, 17, 18 
Furthermore, the study highlights the relatively stronger impairment of HRQoL in PsA 
compared with RA patients, when also taking into consideration levels of joint inflammation, 
as measured by DAS28. Notably, also according to PsA patients’ perspective HRQoL is of 
great importance.1 The severe impact of PsA on HRQoL may possibly be explained by extra-
articular inflammatory affection of e.g. skin or entheses. However, NOR-DMARD does not 
have data on these disease manifestations. We were therefore unable to identify which 
disease manifestations that contributed most to the reduced HRQoL in PsA. Of note, general 
health and vitality were worse in PsA compared with RA patients in all adjusted analyses at 
all time-points.   
RA as well as PsA patients reported better mental than physical HRQoL, which is in line with 
smaller observational studies on SF-36,3 as well as with clinical trials.4, 17 Interestingly, the RA 
and PsA scale score profiles (Figure) were similar to the RA scale score profile found by 
Strand et al.17  
Furthermore, the study is partly in line with two considerably smaller NOR-DMARD studies 
reporting better 6-month improvements in bodily pain and vitality, but not mental health in 
RA compared to PsA patients.19, 20 These studies did not include general population controls.  
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The generic SF-36 facilitated comparison of HRQoL across diseases, although it might 
capture somewhat different aspects of HRQoL than disease-specific measures like e.g. the 
psoriatic arthritis quality of life (PsAQoL).21 
Limitations of the study include lack of 66/68 joint count as well as lack of measures of PsA 
inflammatory activity other than arthritis (e.g. skin involvement, enthesitis, dactylitis and 
spondylitis), which may have led to underestimation of disease activity in PsA as used in the 
DAS28-adjusted analyses. Lack of adjustment for comorbidities may have biased the results, 
although partly corrected for by the age-adjustment. Furthermore, completer analyses may 
have affected the generalisability of the results.  
The major strength of the study is the prospective observational multicentre design 
including large cohorts of RA and PsA patients over a long time span, as well as Norwegian 
general population controls. To our knowledge this is the largest prospective observational 
study comparing SF-36 between RA and PsA patients, and the first to compare SF-36 
component summaries, scale scores as well as SF-6D between RA and PsA patients and 
general population controls in the same analyses.  
In conclusion, HRQoL was overall similar in patients with RA and PsA- with a tendency to 
worse scores in PsA- and worse compared with Norwegian general population controls.  
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